Table S3 from MEN1 Degradation Induced by Neddylation and the CUL4B–DCAF7 Axis Promotes Pancreatic Neuroendocrine Tumor Progression

Table S3 from MEN1 Degradation Induced by Neddylation and the CUL4B–DCAF7 Axis Promotes Pancreatic Neuroendocrine Tumor Progression

<p>Gene mutation analysis identified in 50 patients with PanNETs</p>

Kaydedildi:

Detaylı Bibliyografya
Yazar:	Junfeng Xu (16437141) (author)
Diğer Yazarlar:	Zeng Ye (16437144) (author), Qifeng Zhuo (16437147) (author), Heli Gao (16437150) (author), Yi Qin (15400233) (author), Xin Lou (16437153) (author), Wuhu Zhang (16437156) (author), Fei Wang (16437159) (author), Yan Wang (16437162) (author), Desheng Jing (16437165) (author), Guixiong Fan (16437168) (author), Yue Zhang (16437171) (author), Xuemin Chen (16437174) (author), Jie Chen (16437177) (author), Xiaowu Xu (16437180) (author), Xianjun Yu (16437183) (author), Shunrong Ji (16437186) (author)
Baskı/Yayın Bilgisi:	2025
Konular:	Cancer Cancer Biology Clinical Research and Trials Endocrine-Related Cancers Oncogenes & Tumor Suppressors Precision Medicine Rare Cancers
Etiketler:	Etiketle Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller

Table S2 from MEN1 Degradation Induced by Neddylation and the CUL4B–DCAF7 Axis Promotes Pancreatic Neuroendocrine Tumor Progression
Yazar:: Junfeng Xu (16437141)
Baskı/Yayın Bilgisi: (2025)

Supplementary Data from β-Catenin–Driven Differentiation Is a Tissue-Specific Epigenetic Vulnerability in Adrenal Cancer
Yazar:: Dipika R. Mohan (15011204)
Baskı/Yayın Bilgisi: (2025)

Figure 1 from Systematic Evaluation of the Immune Environment of Small Intestinal Neuroendocrine Tumors
Yazar:: Clare Vesely (505402)
Baskı/Yayın Bilgisi: (2025)

Figure 2 from Systematic Evaluation of the Immune Environment of Small Intestinal Neuroendocrine Tumors
Yazar:: Clare Vesely (505402)
Baskı/Yayın Bilgisi: (2025)

Figure 3 from Systematic Evaluation of the Immune Environment of Small Intestinal Neuroendocrine Tumors
Yazar:: Clare Vesely (505402)
Baskı/Yayın Bilgisi: (2025)

Figure 4 from Systematic Evaluation of the Immune Environment of Small Intestinal Neuroendocrine Tumors
Yazar:: Clare Vesely (505402)
Baskı/Yayın Bilgisi: (2025)

Figure 5 from Systematic Evaluation of the Immune Environment of Small Intestinal Neuroendocrine Tumors
Yazar:: Clare Vesely (505402)
Baskı/Yayın Bilgisi: (2025)

Table 1 from Systematic Evaluation of the Immune Environment of Small Intestinal Neuroendocrine Tumors
Yazar:: Clare Vesely (505402)
Baskı/Yayın Bilgisi: (2025)

Supplementary Tables from Biallelic <i>Dicer1</i> Mutations in the Gynecologic Tract of Mice Drive Lineage-Specific Development of <i>DICER1</i> Syndrome–Associated Cancer
Yazar:: Yemin Wang (17315078)
Baskı/Yayın Bilgisi: (2025)

Supplementary fig 1 from Gene Expression Profiling Identifies Two Chordoma Subtypes Associated with Distinct Molecular Mechanisms and Clinical Outcomes
Yazar:: Jiwei Bai (15051797)
Baskı/Yayın Bilgisi: (2025)

Supplementary fig 2 from Gene Expression Profiling Identifies Two Chordoma Subtypes Associated with Distinct Molecular Mechanisms and Clinical Outcomes
Yazar:: Jiwei Bai (15051797)
Baskı/Yayın Bilgisi: (2025)

Supplementary fig 3 from Gene Expression Profiling Identifies Two Chordoma Subtypes Associated with Distinct Molecular Mechanisms and Clinical Outcomes
Yazar:: Jiwei Bai (15051797)
Baskı/Yayın Bilgisi: (2025)

Supplementary fig 4 from Gene Expression Profiling Identifies Two Chordoma Subtypes Associated with Distinct Molecular Mechanisms and Clinical Outcomes
Yazar:: Jiwei Bai (15051797)
Baskı/Yayın Bilgisi: (2025)

Supplementary fig 5 from Gene Expression Profiling Identifies Two Chordoma Subtypes Associated with Distinct Molecular Mechanisms and Clinical Outcomes
Yazar:: Jiwei Bai (15051797)
Baskı/Yayın Bilgisi: (2025)

Table S1-S5 from Gene Expression Profiling Identifies Two Chordoma Subtypes Associated with Distinct Molecular Mechanisms and Clinical Outcomes
Yazar:: Jiwei Bai (15051797)
Baskı/Yayın Bilgisi: (2025)

Supplementary Figure 1 from A Phase II Clinical Trial of Nivolumab and Temozolomide for Neuroendocrine Neoplasms
Yazar:: Dwight H. Owen (15034782)
Baskı/Yayın Bilgisi: (2025)

Supplementary Figure 2 from A Phase II Clinical Trial of Nivolumab and Temozolomide for Neuroendocrine Neoplasms
Yazar:: Dwight H. Owen (15034782)
Baskı/Yayın Bilgisi: (2025)

Supplementary Figure 3 from A Phase II Clinical Trial of Nivolumab and Temozolomide for Neuroendocrine Neoplasms
Yazar:: Dwight H. Owen (15034782)
Baskı/Yayın Bilgisi: (2025)

Supplementary Figure 4 from A Phase II Clinical Trial of Nivolumab and Temozolomide for Neuroendocrine Neoplasms
Yazar:: Dwight H. Owen (15034782)
Baskı/Yayın Bilgisi: (2025)

Supplementary Figure 5 from A Phase II Clinical Trial of Nivolumab and Temozolomide for Neuroendocrine Neoplasms
Yazar:: Dwight H. Owen (15034782)
Baskı/Yayın Bilgisi: (2025)

Supplementary Data from ONC201 in Combination with Paxalisib for the Treatment of H3K27-Altered Diffuse Midline Glioma
Yazar:: Evangeline R. Jackson (15558808)
Baskı/Yayın Bilgisi: (2025)

العمل بالأكثر والغالب عند الأصوليين: دراسة تطبيقية
Yazar:: Al-mutiri, Aloush Khaled
Baskı/Yayın Bilgisi: (2022)

Figure S7 from LncRNA AGPG Confers Endocrine Resistance in Breast Cancer by Promoting E2F1 Activity
Yazar:: Shiyi Yu (17079079)
Baskı/Yayın Bilgisi: (2025)

Supplementary Data from Epithelial-to-Mesenchymal Transition Supports Ovarian Carcinosarcoma Tumorigenesis and Confers Sensitivity to Microtubule Targeting with Eribulin
Yazar:: Gwo Yaw Ho (14961416)
Baskı/Yayın Bilgisi: (2025)

Spreadsheet index of named bookbinders in the Sotheby's auction catalogues for the sales of the Major John Roland Abbey collection, sold between 1965 and 1989
Yazar:: John Hodgson (22668215)
Baskı/Yayın Bilgisi: (2025)

Table S2 from Combined CDK4/6 and ERK1/2 Inhibition Enhances Antitumor Activity in NF1-Associated Plexiform Neurofibroma
Yazar:: Alyssa C. Flint (16676029)
Baskı/Yayın Bilgisi: (2025)

Table S5 from Combined CDK4/6 and ERK1/2 Inhibition Enhances Antitumor Activity in NF1-Associated Plexiform Neurofibroma
Yazar:: Alyssa C. Flint (16676029)
Baskı/Yayın Bilgisi: (2025)

Video 1_Imaging-driven diagnosis of retroperitoneal psoas major alveolar soft part sarcoma: a case report.mp4
Yazar:: Shasha Wei (1555588)
Baskı/Yayın Bilgisi: (2025)

Figure S1 from Genomic and Transcriptomic Characteristics of Metastatic Thyroid Cancers with Exceptional Responses to Radioactive Iodine Therapy
Yazar:: Laura Boucai (15054310)
Baskı/Yayın Bilgisi: (2025)

Figure S2 from Genomic and Transcriptomic Characteristics of Metastatic Thyroid Cancers with Exceptional Responses to Radioactive Iodine Therapy
Yazar:: Laura Boucai (15054310)
Baskı/Yayın Bilgisi: (2025)

Figure S3 from Genomic and Transcriptomic Characteristics of Metastatic Thyroid Cancers with Exceptional Responses to Radioactive Iodine Therapy
Yazar:: Laura Boucai (15054310)
Baskı/Yayın Bilgisi: (2025)

Figure S4 from Genomic and Transcriptomic Characteristics of Metastatic Thyroid Cancers with Exceptional Responses to Radioactive Iodine Therapy
Yazar:: Laura Boucai (15054310)
Baskı/Yayın Bilgisi: (2025)

Table S1 from Genomic and Transcriptomic Characteristics of Metastatic Thyroid Cancers with Exceptional Responses to Radioactive Iodine Therapy
Yazar:: Laura Boucai (15054310)
Baskı/Yayın Bilgisi: (2025)

Table S2 from Genomic and Transcriptomic Characteristics of Metastatic Thyroid Cancers with Exceptional Responses to Radioactive Iodine Therapy
Yazar:: Laura Boucai (15054310)
Baskı/Yayın Bilgisi: (2025)

Table S3 from Genomic and Transcriptomic Characteristics of Metastatic Thyroid Cancers with Exceptional Responses to Radioactive Iodine Therapy
Yazar:: Laura Boucai (15054310)
Baskı/Yayın Bilgisi: (2025)

Table S4 from Genomic and Transcriptomic Characteristics of Metastatic Thyroid Cancers with Exceptional Responses to Radioactive Iodine Therapy
Yazar:: Laura Boucai (15054310)
Baskı/Yayın Bilgisi: (2025)

Table S5 from Genomic and Transcriptomic Characteristics of Metastatic Thyroid Cancers with Exceptional Responses to Radioactive Iodine Therapy
Yazar:: Laura Boucai (15054310)
Baskı/Yayın Bilgisi: (2025)

Table S6 from Genomic and Transcriptomic Characteristics of Metastatic Thyroid Cancers with Exceptional Responses to Radioactive Iodine Therapy
Yazar:: Laura Boucai (15054310)
Baskı/Yayın Bilgisi: (2025)

Supplementary Table S2 from A Phase II Trial of Guadecitabine in Children and Adults with SDH-Deficient GIST, Pheochromocytoma, Paraganglioma, and HLRCC-Associated Renal Cell Carcinoma
Yazar:: John A. Ligon (15024477)
Baskı/Yayın Bilgisi: (2025)

Supplementary file 1_Cost-effectiveness analysis of first-line versus second-line use of CDK4/6 inhibitors combined with endocrine therapy in advanced HR+/HER2- breast cancer in China: based on the SONIA trial.docx
Yazar:: Xiaohu Jin (9618675)
Baskı/Yayın Bilgisi: (2025)

Cannot write session to /tmp/vufind_sessions/sess_b7grjrl1asfjsh9rmv8h4e0sjh